You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Mallinckrodt
McKinsey
Boehringer Ingelheim
Baxter

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,050,335

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,050,335 protect, and when does it expire?

Patent 9,050,335 protects XARTEMIS XR and is included in one NDA.

Summary for Patent: 9,050,335
Title:Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
Abstract: The present disclosure provides extended release pharmaceutical compositions comprising oxycodone and acetaminophen that produce a quick initial onset of analgesia, yet, maintain analgesia for about 12 hours after administration of the composition to a subject in need thereof. The pharmaceutical compositions disclosed herein also reduce the levels of acetaminophen in a subject's blood near the end of the dosing interval because the acetaminophen released by the pharmaceutical composition is being eliminated by a subjects body faster than it is being absorbed.
Inventor(s): Devarakonda; Krishna (St. Louis, MO), Giuliani; Michael J. (Creve Coeur, MO), Gupta; Vishal K. (Hillsborough, NJ), Heasley; Ralph A. (Webster Groves, MO), Shelby; Susan (Creve Coeur, MO)
Assignee: MALLINCKRODT LLC (Hazelwood, MO)
Application Number:13/473,586
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,050,335
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Formulation; Device;

Drugs Protected by US Patent 9,050,335

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mallinckrodt Inc XARTEMIS XR acetaminophen; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 204031-001 Mar 11, 2014 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Medtronic
Boehringer Ingelheim
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.